Other languages Exelixis, Inc.

Equities

EXEL

US30161Q1040

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
23.53 ^USD	-0.76%		+4.62%	-1.92%

Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ
Apr. 11	Barclays Downgrades Exelixis to Equalweight From Overweight, Price Target is $25	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jacqueline Wright Notifies Exelixis, Inc. of Her Decision Not to Stand for Re-Election to the Board of Directors	Mar. 29
Exelixis Insider Bought Shares Worth $3,932,734, According to a Recent SEC Filing	Feb. 22
Exelixis Swings to Earnings in Fiscal Q4 as Sales Increase; 2024 Revenue Guidance Set	Feb. 06
Exelixis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 06
Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024	Feb. 06
Exelixis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 06
Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024	Jan. 25
Ipsen s'apprête à présenter de nouvelles données positives sur le Cabometyx	Jan. 23
Bristol-Myers Squibb, Exelixis Say Opdivo Plus Cabometyx Continue to Show Benefits in Kidney Cancer Trial	Jan. 22
Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib)	Jan. 22
Exelixis Sees Fiscal 2023 Revenue at Lower End of Guidance; Issues Fiscal 2024 Revenue Outlook	Jan. 08
Exelixis, Inc. announces an Equity Buyback for $450 million worth of its shares.	Jan. 08
Exelixis, Inc. Provides Earnings Guidance for Fiscal Year 2024	Jan. 07
Exelixis, Inc. Announces Board Changes	Jan. 07
Exelixis, Inc. authorizes a Buyback Plan.	Jan. 07
Exelixis Insider Sold Shares Worth $1,485,853, According to a Recent SEC Filing	Dec. 15
Exelixis Insider Sold Shares Worth $575,250, According to a Recent SEC Filing	Dec. 15
Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer	Dec. 04
Exelixis, Inc. and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with Ab521 in Patients with Advanced Renal Cell Carcinoma	Dec. 04
Exelixis Insider Bought Shares Worth $2,602,038, According to a Recent SEC Filing	Nov. 29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Exelixis, Inc.

Equities

EXEL

US30161Q1040

Other languages

Filters